Literature DB >> 7083189

Relationship of obesity to blood estrogens.

B Zumoff.   

Abstract

It has become conventional wisdom that estrogenic stimulation of breast tissue has something to do with the causation of breast cancer and that the reason obesity is a risk factor for breast cancer is that obese women are hyperestrogenized. However, it has been very difficult to demonstrate that excessive exogenous estrogen increases the incidence of breast cancer, that endogenous estrogen excess is present in breast cancer, or that obese women are hyperestrogenized. We have examined the last question by measuring 24-hr mean plasma estrone and estradiol levels in the midfollicular phase in 18 healthy, regularly cycling, very obese (53 to 218% above ideal weight) women and 16 regularly cycling, age matched, nonobese control women. Unlike obese men, the obese women showed no significant elevation of either estrone or estradiol. Their average estrone level was 72 compared with 64 pg/ml in controls; their average estradiol level was 65 compared with 57 pg/ml in controls. In the combined group (obese plus nonobese), there was a significant correlation of percentage of deviation from ideal weight with plasma estrone (y = 63 + 0.12x; p less than 0.05) but not with estradiol. This correlation supports the current hypothesis that there is increased androstenedione leads to estrone conversion (i.e., increased aromatase activity) in obesity. The reason plasma estrone levels are not significantly elevated in obese women is that the small amount derived from androstenedione is swamped by the much larger amount derived from ovarian secretion, which is apparently unaffected by obesity. Unless there is increased local formation of estrogens in the breast tissue of obese women, the absence of elevated plasma estrogens in them means that their breasts are not "seeing" increased estrogen levels. Thus, endogenous hyperestrogenization is unlikely to be a causative factor of breast cancer in obese women.U

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

2.  Serum lipid levels in benign prostatic hyperplasia.

Authors:  Murat Lekili; Talha Müezzinoğlu; Bekir Sami Uyanik; Coşkun Büyüksu
Journal:  World J Urol       Date:  2006-02-28       Impact factor: 4.226

Review 3.  Hormone replacement therapy and the risk of breast cancer.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

4.  Body size in relation to urinary estrogens and estrogen metabolites (EM) among premenopausal women during the luteal phase.

Authors:  Jing Xie; A Heather Eliassen; Xia Xu; Charles E Matthews; Susan E Hankinson; Regina G Ziegler; Shelley S Tworoger
Journal:  Horm Cancer       Date:  2012-08-04       Impact factor: 3.869

5.  Fat intake, obesity, and cancer of the breast and endometrium.

Authors:  A P Simopoulos
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 6.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

7.  The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States).

Authors:  J F Dorgan; M E Reichman; J T Judd; C Brown; C Longcope; A Schatzkin; D Albanes; W S Campbell; C Franz; L Kahle
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

Review 8.  Exemestane for breast cancer prevention: a critical shift?

Authors:  Andrea Decensi; Barbara K Dunn; Matteo Puntoni; Alessandra Gennari; Leslie G Ford
Journal:  Cancer Discov       Date:  2012-01       Impact factor: 39.397

9.  Early adult body weight, body mass index, and premenopausal bilateral breast cancer: data from a case-control study.

Authors:  G Ursin; A Paganini-Hill; J Siemiatycki; W D Thompson; R W Haile
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.

Authors:  T J Key; M C Pike
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.